Stryker Corporation $SYK Shares Bought by Advisors Capital Management LLC

Advisors Capital Management LLC lifted its position in Stryker Corporation (NYSE:SYK) by 2.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,935 shares of the medical technology company’s stock after acquiring an additional 1,711 shares during the period. Advisors Capital Management LLC’s holdings in Stryker were worth $24,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Stryker during the 1st quarter worth about $558,075,000. Price T Rowe Associates Inc. MD raised its position in shares of Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after acquiring an additional 1,021,496 shares during the period. Alliancebernstein L.P. grew its holdings in Stryker by 66.7% in the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after purchasing an additional 549,643 shares during the period. Vanguard Group Inc. raised its position in Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after acquiring an additional 361,136 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after purchasing an additional 261,058 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 520,500 shares of company stock valued at $184,803,065 in the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Stryker Trading Up 1.5%

NYSE SYK opened at $372.93 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $372.55 and a 200 day moving average price of $381.18. The stock has a market capitalization of $142.62 billion, a P/E ratio of 49.40, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the prior year, the company posted $2.87 earnings per share. Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Analyst Ratings Changes

SYK has been the topic of several research reports. Redburn Partners set a $420.00 price target on shares of Stryker in a research note on Thursday, September 18th. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Rothschild & Co Redburn assumed coverage on Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. BTIG Research boosted their price target on shares of Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Weiss Ratings lowered Stryker from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, November 7th. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $433.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.